Brief: Garuda Therapeutics Closes $50 Million Series A-1 Financing To Advance Off-The-Shelf Blood Stem Cell Therapies
March 4 (Reuters) - Kyowa Kirin Co Ltd 4151.T: GARUDA THERAPEUTICS CLOSES $50 MILLION SERIES A-1 FINANCING TO ADVANCE OFF-THE-SHELF BLOOD STEM CELL THERAPIES GARUDA: INVESTORS INCLUDED ORBIMED, NORTHPOND VENTURES AND CORMORANT ASSET MANAGEMENT, WITH NEW STRATEGIC INVESTMENT FROM KYOWA KIRIN CO., LTD Source text: ID:nGNX9G7mV9 Further company coverage: 4151.T (Reuters.Briefs@thomsonreuters.com)
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia